Clinical Trials Directory

Trials / Completed

CompletedNCT01139047

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% vs Finacea® (Azelaic Acid) 15% in Subjects With Healthy Skin

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
77 (actual)
Sponsor
Galderma R&D · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.

Conditions

Interventions

TypeNameDescription
DRUGmetronidazole 1% gelApply topically once daily on one side of the face for three weeks
DRUGazelaic acid 15% gelApply topically twice daily on the opposite side of the face for three weeks

Timeline

Start date
2010-06-01
Primary completion
2010-06-01
Completion
2010-06-01
First posted
2010-06-08
Last updated
2022-08-01
Results posted
2011-07-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01139047. Inclusion in this directory is not an endorsement.

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin (NCT01139047) · Clinical Trials Directory